HBeAg-negative Patients with Chronic Hepatitis B Virus Infection and Normal Alanine Aminotransferase:Wait or Treat?

查看全文 作　　者：Qiuju [1]Sheng;Ning [1]Wang;Chong [1]Zhang;Yaoxin [1]Fan;Yanwei [1]Li;Chao [1]Han;Ziyi [1]Wang;Shuqi [1]Wei;Xiaoguang [1]Dou;Yang [1]Ding

机构地区：[1]Department of Infectious Diseases,Shengjing Hospital of China Medical University,Shenyang,Liaoning,China

出　　处：《Journal of Clinical and Translational Hepatology》索引2022年第10卷第5期,共7页

基　　金：supported by grants from the Liaoning Pro-vincial Natural Science Foundation Project(No.2019-ZD-0788);the 345 Talent Project of Shengjing Hospital(No.2021-01). 摘　　要：Alanine aminotransferase(ALT)is a common clinical indicator of liver inflammation.The current Chinese guidelines for the management of chronic hepatitis B(CHB)recommend antiviral treatment for patients with detectable hepatitis B virus(HBV)DNA and persistent ALT levels(ALTs)exceeding the upper limit of normal.However,it has been recently reported that patients with chronic HBV infection,especially HBeAg-negative patients with persistently normal ALTs,may have liver biopsy findings of significant inflammation and fibrosis.For HBeAg-negative patients with chronic HBV infection and normal ALTs,many controversial questions have been asked.To treat or not?When to initiate the treatment?Which drug is appropriate?In this review,we summarize the available data on the management of HBeAg-negative patients with chronic HBV infection and normal ALTs with the aim of improving the current clinical management. 关键词：Hepatitis B virus Chronic hepatitis B Hepatitis e antigen Alanine aminotransferase Antiviral therapy

相关文献

参考文献（38）
引证文献（7）
耦合文献（324）

参考文献(38)

引证文献(7)

耦合文献(324)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

HBeAg-negative Patients with Chronic Hepatitis B Virus Infection and Normal Alanine Aminotransferase:Wait or Treat?

参考文献(38)

引证文献(7)

耦合文献(324)

用户提示